Ratings Legend Biotech Corporation

Equities

LEGN

US52490G1022

Market Closed - Nasdaq 21:00:00 18/06/2024 BST 5-day change 1st Jan Change
40.48 USD -2.46% Intraday chart for Legend Biotech Corporation -8.52% -32.72%

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
-32.72% 7.38B
D
+14.84% 121B
B+
+18.31% 112B
B+
+1.75% 22.72B
B
-18.26% 20.82B
B+
-41.55% 16.36B
A-
-14.23% 16.19B
B
-17.94% 16.66B
A-
-0.68% 13.17B
C+
+21.87% 11.11B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. LEGN Stock
  4. Ratings Legend Biotech Corporation
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW